Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

Abstract

Background Since the prevalence of obesity continues to increase, there is a demand for effective and safe anti-obesity agents that can produce and maintain weight loss and improve comorbidity. We did a meta-analysis of all published randomised controlled trials to assess the efficacy and safety of the newly approved anti-obesity agent rimonabant.Methods We searched The Cochrane database and Controlled Trials Register, Medline via Pubmed, Embase via WebSpirs, Web of Science, Scopus, and reference lists up to July, 2007. We collected data from four double-blind, randomised controlled trials (including 4105 participants) that compared 20 mg per day rimonabant with placebo.Findings Patients given rimonabant had a 4.7 kg (95% CI 4.1-5.3 kg; p<0.0001) greater weight reduction after 1 year than did those given placebo. Rimonabant caused significantly more adverse events than did placebo (OR=1.4; p=0.0007; number needed to harm=25 individuals [95% CI 17-58]), and 1.4 times more serious adverse events (OR=1.4; p=0.03; number needed to harm=59 [27-830]). Patients given rimonabant were 2.5 times more likely to discontinue the treatment because of depressive mood disorders than were those given placebo (OR=2.5; p=0.01; number needed to harm=49 [19-316]). Furthermore, anxiety caused more patients to discontinue treatment in rimonabant groups than in placebo groups (OR=3.0; p=0.03; number needed to harm=166 [47-3716]).Interpretation Our findings suggest that 20 mg per day rimonabant increases the risk of psychiatric adverse events--ie, depressed mood disorders and anxiety-despite depressed mood being an exclusion criterion in these trials. Taken together with the recent US Food and Drug Administration finding of increased risk of suicide during treatment with rimonabant, we recommend increased alertness by physicians to these potentially severe psychiatric adverse reactions.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(07)61721-8

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Cited by

See all 1,097

Metadata

Authors
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A.
Affiliations
  • Frederiksberg Hospital (DK)
  • University of Copenhagen (DK)
Venue
The Lancet
Publisher
Elsevier BV
Published
2007-11
Volume
370
Issue
9600
Pages
1706-1713
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2123907272
Cited by
1,097
References
49
Citations by year
2026: 34 · 2025: 48 · 2024: 50 · 2023: 39 · 2022: 35 · 2021: 63 · 2020: 70 · 2019: 51 · 2018: 56 · 2017: 57 · 2016: 53 · 2015: 52 · 2014: 59 · 2013: 46 · 2012: 60
FWCI
8.81
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
Parker Institute for Cancer Immunotherapy
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
rimonabant, anti-obesity drugs, weight loss, obesity, adverse events, psychiatric adverse effects, depression, anxiety, treatment discontinuation, suicide risk, drug safety
MeSH terms
Rimonabant, Anxiety Disorders, Depression, Double-Blind Method, Female, Humans, Male, Obesity, Piperidines, Pyrazoles, Multicenter Studies as Topic, Weight Loss, Randomized Controlled Trials as Topic, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. https://app.cochat.ai/papers/10.1016/s0140-6736(07)61721-8
The paper
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. The Lancet. https://doi.org/10.1016/s0140-6736(07)61721-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.